Close Menu

NEW YORK ─ Leinco Technologies said today it has entered into an agreement with Vanderbilt University Medical Center (VUMC) to scale up production of its most promising antibodies for development of an immunodiagnostic test for the detection of SARS-CoV-2, the virus that causes COVID-19.

Fenton, Missouri-based Leinco Technologies said that under the agreement it will co-develop a test that has antibody sequences discovered in the Nashville, Tennessee-based Vanderbilt Vaccine Center (VVC).

Financial and other terms of the agreement were not disclosed.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sponsored by
Thermo Fisher Scientific

With COVID-19 vaccines rolling out, clinical labs and test developers are preparing for changes in both demand for testing and types of testing for SARS-CoV-2.

Sponsored by

Amid the COVID-19 pandemic, hospitals and intensive care units around the world have been overwhelmed by unprecedented levels of demand. 

Sponsored by
LGC SeraCare Life Sciences

As we pass the one-year anniversary of both the COVID-19 pandemic and the first Emergency Use Authorized SARS-CoV-2 PCR detection assays, there remains significant opportunity for clinical laboratories to advance testing and support improved patient management.

Sponsored by

This webinar will present the details of a COVID-19 saliva screening program that has been implemented at more than 90 different colleges, universities, private schools, and nursing homes across New York state.